Response letter to the editor about the editorial by oppenheimer and greenberger “baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO” (2017;119:474-5)
Publication date: Available online 12 March 2018 Source:Annals of Allergy, Asthma & Immunology Author(s): Paul A. Greenberger, John j. Oppenheimer
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου